医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

FIMECS, Inc. Concludes Licensing Agreement with Takeda to Develop Novel Immuno-Oncology Therapies

2018年04月10日 PM08:00
このエントリーをはてなブックマークに追加


 

KANAGAWA, Japan

FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on protein degradation, today announced it has concluded a strategic licensing agreement with Takeda Pharmaceutical Co., Ltd. (“Takeda”). FIMECS raised 250M JPY (US$~2.3M) in funding by third-party allocation of shares underwritten by Cosmo Bio Co., Ltd. and Takeda to research and develop first-in-class protein degradation therapeutics for the treatment of cancer.

Under the licensing agreement, the company received compound assets including first-in-class E3 ligase binders and novel pseudokinase targeting binders, which enable the acceleration of protein degradation therapeutics to ‘undruggable’ targets — a critical area of cancer research requiring new innovation.

“We are excited by the momentum of FIMECS and to make Shonan Health Innovation Park our new home for developing meaningful innovations in difficult-to-target protein degradation,” said Yusuke Tominari, Co-founder and CEO. “Our mission is to create innovative modalities to access expanded cancer targets previously thought to be ‘undruggable’ and contribute to the delivery of new and lifesaving medicines to patients around the world.”

FIMECS is among the first biotechnology companies to reside at Shonan Health Innovation Park, a newly formed ecosystem for innovation built in Shonan, Japan. The Park is focused on bringing together industry, government, academia and entrepreneurs to accelerate the translation of cutting-edge science into impactful health solutions for patients in Japan and around the world.

“I am pleased to welcome FIMECS as our newest resident,” said Toshio Fujimoto, general manager of the Shonan Health Innovation Park. “FIMECS represents an ideal partner for Shonan Health Innovation Park, which promotes open innovation. I believe that with our scientific resources, facilities and structures, Shonan Health Innovation Park can support FIMECS and other ambitious companies as they overcome technological challenges and accelerate the successful development of new medicines.”

About FIMECS, Inc.

FIMECS, Inc. is developing a new class of targeted protein degradation therapeutics for the treatment of cancer diseases. The company is focused on creating a new class of drugs based on protein degradation for ‘undruggable’ cancer targets – a term coined by industry to describe proteins that could not be targeted pharmacologically. By integrating proprietary E3 ligase binder with molecule-designing capability, the company seeks to discover therapeutic candidates to rapidly induce the degradation of targeted (disease-relevant) proteins through natural ubiquitin/proteasome system mechanisms. Utilizing our drug discovery platform to internal project and collaboration project, the company seeks to provide life-saving medicine to patients all over the world.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180410005788/en/

CONTACT

FIMECS, Inc. Media Contact:
Yusuke Kohno, VP Corporate
Development
+81-466-32-1169
info@fimecs.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • BioDuro-Sundia Completes First GMP Drug Product Manufacturing at New China Site
  • Illumina Named One of Singapore’s Best Employers
  • BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021
  • Diaceutics Appoints Yvanka Gilliam as Vice President of Operations, Asia Pacific
  • Avaya’s “Life and Work Beyond 2020” Survey Reveals Organizations Play Key Role in Individuals’ Well-Being